249296-44-4
249296-44-4 structure
- Name: Varenicline
- Chemical Name: varenicline
- CAS Number: 249296-44-4
- Molecular Formula: C13H13N3
- Molecular Weight: 211.26
- Catalog: Signaling Pathways Membrane Transporter/Ion Channel nAChR
- Create Date: 2018-08-07 11:17:07
- Modify Date: 2024-01-02 11:47:42
-
Varenicline(CP 526555;Champix) is a selective α4β2 nicotinic receptor partial agonist; it stimulates nicotine receptors more weakly than nicotine itself does.IC50 value:Target: nAChRVarenicline(CP 526555; Champix; Chantix) is a prescription medication used to treat smoking addiction. As a partial agonist it both reduces cravings for and decreases the pleasurable effects of cigarettes and other tobacco products. Through these mechanisms Varenicline(CP 526555; Champix; Chantix) can assist some patients to quit smoking.
| Name | varenicline |
|---|---|
| Synonyms |
Vareniclene
Chantix 10-tetrahydro 10-Methano-6H-pyrazino[2 5,8,14-triazatetracycIo[10.3.1.0(2,11).0(4,9)]hexadeca-2(11),3,5,7,9-pentaene 5,8,14-triazatetracyclo[10.3.1.0(2,11),0(4,9)]hexadeca-2(l11),3,5,7,9-pentaene 3-h][3]benzazepine 5,8,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]hexadeca-2(11),3,5,7,9-pentaene Varenicline 7,8,9,10-tetrahydro-6,10-methano-6H-pyrazino[2,3-h][3]benzazepine Unii-W6hs99o8zo |
| Description | Varenicline(CP 526555;Champix) is a selective α4β2 nicotinic receptor partial agonist; it stimulates nicotine receptors more weakly than nicotine itself does.IC50 value:Target: nAChRVarenicline(CP 526555; Champix; Chantix) is a prescription medication used to treat smoking addiction. As a partial agonist it both reduces cravings for and decreases the pleasurable effects of cigarettes and other tobacco products. Through these mechanisms Varenicline(CP 526555; Champix; Chantix) can assist some patients to quit smoking. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.247g/cm3 |
|---|---|
| Boiling Point | 400.6ºC at 760mmHg |
| Molecular Formula | C13H13N3 |
| Molecular Weight | 211.26 |
| Flash Point | 196.1ºC |
| PSA | 152.87000 |
| LogP | 0.01010 |
| Vapour Pressure | 1.25E-06mmHg at 25°C |
| Index of Refraction | 1.667 |
| Storage condition | 2-8℃ |
|
~83%
249296-44-4 |
| Literature: Teva Pharmaceutical Industries Ltd. Patent: US2010/324055 A1, 2010 ; Location in patent: Page/Page column 4-5 ; |
|
~68%
249296-44-4 |
| Literature: Teva Pharmaceutical Industries Ltd. Patent: US2010/324055 A1, 2010 ; Location in patent: Page/Page column 5 ; |
|
~61%
249296-44-4 |
| Literature: Teva Pharmaceutical Industries Ltd. Patent: US2010/324055 A1, 2010 ; Location in patent: Page/Page column 5 ; |
|
~96%
249296-44-4 |
| Literature: TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC. Patent: WO2009/143347 A2, 2009 ; Location in patent: Page/Page column 25 ; |
|
~65%
249296-44-4 |
| Literature: Pasikanti, Srinivas; Srinivasa Reddy; Venkatesham; Dubey; Iqbal, Javed; Das, Parthasarathi Tetrahedron Letters, 2010 , vol. 51, # 1 p. 151 - 152 |
| Precursor 1 | |
|---|---|
| DownStream 1 | |
